Abstract 1743P
Background
Gender disparities in academic research in oncology remain a persistent global challenge. There is a significant lack of research on gender inequity in Africa. GEORGiNA (“Gender Equity in Oncology Research” Group of North Africa) is a gender focusing bibliometric study that reviewed cancer research of North-African countries intending to build policy, recommendations, and gender equality actions in the field of cancer research.
Methods
A Pubmed-based bibliometric analysis was conducted over 2018-2022 period. Eligible articles had at least one author from a North-African country in the first or last position. Cancer researchers reviewed articles with authors from their own country to determine their gender accurately. A manual data extraction guide was developed and shared with collaborators to ensure consistent and accurate reporting. Factors associated with gender distribution were studied as appropriate.
Results
A total of 7,109 articles (2018-2022) published by North-African oncologists were included in the bibliometric analysis. Females represented 51% of first authors, with a notable women’s presence in Tunisia (71.9%). Morocco, Algeria, and Egypt demonstrated a fair distribution of female first authors with ratios close to 0.5, while Sudan and Libya exhibited male dominance with percentages of 62% and 70%, respectively. Among 37,019 of co-authors, 44.13 % (n=16,333) were females. Male oncologists were found to have significantly higher representation as principal investigators (PIs) in all countries (p < 0.001). Notably, there has been a remarkable increase in women taking lead authorship roles in recent years, including during the period of the COVID-19 pandemic. Male researchers dominated original articles as PIs (p < 0.001). Indeed, male had received more funding than females and published more open access science (p<0.01). There was a significant difference observed in the involvement of male authors (both first and last positions) in international collaboration compared to females in equivalent positions.
Conclusions
While women in cancer research appear to achieve a fair position, there are still barriers such as insufficient funding and limited international collaboration to drive progress towards gender equity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
K. El Bairi and GEORGiNA study collaborators.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1902P - Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
Presenter: Audreylie Lemelin
Session: Poster session 23
1903P - Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial
Presenter: Viktor Gruenwald
Session: Poster session 23
1904P - Treatment options and outcome of metastatic renal cell carcinoma patients with brain or bone metastases: A real-world evidence from a German retrospective multi-center analysis
Presenter: Pia Paffenholz
Session: Poster session 23
1905P - Heterogeneity in tertiary lymphoid structures predicts the distinct prognosis and immune microenvironment of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster session 23
1906P - Metastasized non-clear cell renal cell carcinoma: Which entities are dangerous? Results learned from reference pathology of the SuniForecast study
Presenter: Arndt Hartmann
Session: Poster session 23
1907P - Multi-omics mapping positions antigenic myeloid-T cell crosstalk at the core of advanced renal cell carcinoma (aRCC) response to immune checkpoint blockade (ICB)
Presenter: Lisa Kinget
Session: Poster session 23
1908P - Utility of circulating tumor (ct)DNA testing for molecular residual disease (MRD) detection and treatment response monitoring in patients (pts) with renal cell carcinoma (RCC)
Presenter: Michael Smigelski
Session: Poster session 23
1909P - Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study
Presenter: Larissa Rainho
Session: Poster session 23
1910P - Evaluation of a genome-wide methylome enrichment platform for circulating tumor DNA quantification and prognostic performance in renal cell carcinoma (RCC)
Presenter: Brian Rini
Session: Poster session 23
1911P - Effect of VHL mutations on efficacy of immune checkpoint inhibitors in renal cell carcinoma
Presenter: Guojie Yu
Session: Poster session 23